T
Tafalgie Therapeutics
Next-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals
About Tafalgie Therapeutics
Tafalgie Therapeutics is a French biopharmaceutical startup that specializes in the development of non-opioid drugs for the treatment of chronic, severe, or persistent pain. The company is a spin-off from the French National Centre for Scientific Research (CNRS) and Aix-Marseille University (AMU). Their primary focus is on creating a new scientific approach for next-generation treatments, which are based on an innovative mechanism of action derived from a protein capable of modulating pain signals. This is a significant breakthrough in the medical field, especially considering the current opioid crisis.
Read full description
Tafalgie Therapeutics serves a broad range of clients, including patients suffering from acute severe pain and chronic refractory pain. The company operates in the global pharmaceutical market, which is expected to reach $100 billion by 2030. Their business model revolves around the research, development, and commercialization of their unique, non-addictive pain relief drugs.
The company generates revenue through the sale of these drugs, which are designed to provide high-efficacy, high-tolerability, and non-addictive solutions for pain management. They are also dedicated to the prevention and treatment of chronic refractory pain, a condition that is often inadequately treated.
In summary, Tafalgie Therapeutics is a promising startup in the pharmaceutical industry, with a unique approach to pain management that could revolutionize the treatment of chronic and severe pain.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Marseille, France
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 88.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Rehabilitation, Biotechnology, Spinout, EIC, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Horizon Europe
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2025 | $13M | $53M | Bpifrance | ↗ |
| GRANT✓Other financing | Jun 2023 | $2.5M | — | European Innovation Council | — |
Growth signals
Latest recorded traffic for Tafalgie Therapeutics is 1.6K monthly website visits, up 63.3% over the last three months. Tafalgie Therapeutics's team grew 26.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Laurent Labatut
Eric Schettini
European Innovation Council
Series A1 investor entered at this stage
Other known investors5 additional known investors
CNRS Innovation
French National Centre for Scientific Research - CNRS
Incubateur Impulse
SATT Sud-Est
ROC Global Opportunities
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tafalgie Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tafalgie Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.